Register a trial

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06375512




Registration number
NCT06375512
Ethics application status
Date submitted
17/04/2024
Date registered
19/04/2024

Titles & IDs
Public title
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
Scientific title
A Phase 1, Randomized, Multicenter, Double-blind, Dose-ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants 50 to 69 Years Old
Secondary ID [1] 0 0
IN001001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Herpes Zoster 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - HZ Vaccine (IN001)
Treatment: Other - Placebo
Treatment: Other - Shingrix

Experimental: Arm 1: Dose A - Participants will receive placebo by intramuscular (IM) injection on Day 0 followed with IN001 by IM injection on Day 56.

Experimental: Arm 2: Dose B - Participants will receive IN001 by IM injection on Day 0 and Day 56.

Experimental: Arm 3: Dose C - Participants will receive IN001 by IM injection on Day 0 and Day 56.

Experimental: Arm 4: Dose D - Participants will receive IN001 by IM injection on Day 0 and Day 56.

Active comparator: Arm 5: Shingrix - Participants will receive Shingrix by IM injection on Day 0 and Day 56.


Treatment: Other: HZ Vaccine (IN001)
Formulation for injection

Treatment: Other: Placebo
0.9% sodium chloride (normal saline) for injection

Treatment: Other: Shingrix
Sterile suspension for injection
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Reporting Solicited Local Reactions
Timepoint [1] 0 0
For 14 days after each vaccination
Primary outcome [2] 0 0
Percentage of Participants Reporting Solicited Systemic Reactions
Timepoint [2] 0 0
For 14 days after each vaccination
Primary outcome [3] 0 0
Percentage of Participants With Unsolicited Adverse Events (AEs)
Timepoint [3] 0 0
For 28 days after each vaccination
Primary outcome [4] 0 0
Percentage of Participants With Any Medically Attended AEs (MAAEs)
Timepoint [4] 0 0
From initial vaccination to 6 months after the second vaccination
Primary outcome [5] 0 0
Percentage of Participants With Any Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), AEs Leading to Vaccine Discontinuation, and AEs Leading to Study Withdrawal
Timepoint [5] 0 0
From initial vaccination to 12 months after the second vaccination
Secondary outcome [1] 0 0
Geometric Mean Concentration (GMC) of Anti-glycoprotein E (gE) Antibodies as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)
Timepoint [1] 0 0
Baseline (before first vaccination); 28 and 56 days post-first vaccination; 14 and 28 days and 3, 6 and 12 months post-second vaccination
Secondary outcome [2] 0 0
Change from Baseline in Geometric Mean Fold Rise (GMFR) of Anti-gE Antibodies as Measured by ELISA
Timepoint [2] 0 0
28 and 56 days post-first vaccination; 14 and 28 days and 3, 6 and 12 months post-second vaccination
Secondary outcome [3] 0 0
Proportion of Participants with Vaccine Response in Anti-gE Antibodies as Measured by ELISA
Timepoint [3] 0 0
28 and 56 days post-first vaccination; 14 and 28 days and 3, 6 and 12 months post-second vaccination
Secondary outcome [4] 0 0
Geometric Mean Titer (GMT) of Anti-VZV Neutralizing Antibodies as Measured by Neutralization Assay
Timepoint [4] 0 0
baseline (before first vaccination); 56 days post-first vaccination; 28 days and 6 and 12 months post-second vaccination
Secondary outcome [5] 0 0
Change from Baseline in GMFR of Anti-VZV Neutralizing Antibodies as Measured by Neutralization Assay
Timepoint [5] 0 0
56 days post-first vaccination; 28 days and 6 and 12 months post-second vaccination
Secondary outcome [6] 0 0
Proportion of Participants with Vaccine Response in Anti-VZV Neutralizing Antibodies as Measured by Neutralization Assay
Timepoint [6] 0 0
56 days post-first vaccination; 28 days and 6 and 12 months post-second vaccination
Secondary outcome [7] 0 0
gE-specific T Cell Response (IFN-? and IL-4 Secreting T Cells) as Measured by Enzyme-Linked Immunospot (ELISpot)
Timepoint [7] 0 0
Baseline (before first vaccination); 28 and 56 days post-first vaccination; 28 days and 3, 6 and 12 months post-second vaccination
Secondary outcome [8] 0 0
Frequencies of gE-specific CD4+ and CD8+ T Cells Expressing Activation Markers (i.e., IFN-?, IL-2, TNFa, CD40L) as Measured by Intracellular Cytokine Staining (ICS)
Timepoint [8] 0 0
Baseline (before first vaccination); 56 days post-first vaccination; 14 and 28 days post-second vaccination

Eligibility
Key inclusion criteria
Key

1. Healthy male or female participants aged between 50 to 69 years of age, inclusive.
2. Body weight = 50 kg for males and = 45 kg for females and body mass index (BMI) in the range of 18.5 to 35 kg/m^2.
3. Participants with asymptomatic medical conditions (eg, hypertension, dyslipidemia) that are not associated with end-organ damage may be included provided they are being appropriately treated as per standard of care, are clinically stable, and are not receiving treatments that would be exclusionary in the opinion of the Investigator.
4. For all women of childbearing potential (WOCBP) females must be non-pregnant and non-lactating and must use a highly effective contraceptive method from at least 30 days prior to enrollment through to 6 months after second vaccination.
5. Willing to provide documented informed consent and comply with the requirements of the clinical study protocol.

Key
Minimum age
50 Years
Maximum age
69 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Participants with a known history of HZ.
2. Participants with a known history of GBS, encephalomyelitis, or transverse myelitis.
3. Participants with a known history of heart disease (eg, heart failure, recent coronary artery disease, myocarditis, pericarditis, or cardiomyopathy).
4. Participants with acute medical illness or febrile illness, including oral temperature = 38.0°C (= 100.4°F) within 1 day prior to screening. Participants with suspected or confirmed COVID-19 should be excluded and referred for medical care.
5. Participants with any medical, neurological, or psychiatric condition that, in the opinion of the Investigator, could place the participant at an unacceptable risk of injury or render the participant unable to comply with all study procedures and achieve successful completion of the trial.
6. Participants with a known history of hypersensitivity reactions including anaphylaxis and urticaria, or other significant adverse reactions to IN001 or its excipients; or participants with a known history of severe allergic reaction (eg, anaphylaxis) to any component of SHINGRIX™ or after a previous dose of SHINGRIX™.
7. Participants who have a positive pregnancy test at the screening visit or who intend to become pregnant during or breastfeed through Study Day 236 (6 months after second vaccination).
8. Participants with uncontrolled hypertension (supine systolic blood pressure = 140 mmHg or supine average diastolic blood pressure = 90 mmHg at screening).
9. Participants with a history of significant hematologic abnormalities or history of thrombosis with thrombocytopenia syndrome.
10. Participants with hematology and/or clinical chemistry laboratory result(s) that meet the definition of a Grade = 2 abnormality as delineated in the FDA guidance.
11. Participants with a history of congenital or acquired immunodeficiency.
12. Participants with an immunosuppressive or immunodeficient state, asplenia, or recurrent severe infections.
13. Participants with a known history of chronic infection including, but not limited to, human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and active tuberculosis.
14. Positive HBV and HCV panel and/or positive HIV test.
15. Participants with positive syphilis test.
16. Participants with chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial participation or interpretation of study results.
17. Participants with a known history of vaccination against varicella or HZ.
18. Participants who have received immunoglobulins and/or any blood or blood products within 4 months before the first study vaccination or who plan to receive such products at any time during the study.
19. Participants who have received immunomodulatory, immunostimulatory, or immunosuppressant drugs including interferon and cytotoxic drugs within 3 months of screening (or 5 half-lives, whichever is longer) or who plan to receive them across the duration of the study.
20. Participants requiring systemic corticosteroids exceeding 10 mg/day of prednisone equivalent for = 10 days within 30 days of screening. The use of topical, ophthalmic, inhaled, and intranasal steroid preparations will be permitted.
21. Participants who have received or plan to receive any licensed vaccine = 28 days prior to the first vaccination (Day 0) or who plan to receive a licensed vaccine = 28 days after the first study vaccination or = 28 days before or after the second study vaccination. The only exception is licensed inactivated influenza vaccine or non-replicating influenza vaccine, which may be given = 14 days before or = 28 days after receipt the first or second study vaccination.
22. Participants receiving treatment with another investigational drug, biological agent, or device = 28 days of screening, or 5 half-lives of the investigational drug, whichever is longer; or currently enrolled in or plans to participate in another clinical trial with an investigational agent during the study period (including the follow-up period of the study).
23. Participants with history of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.
24. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week.
25. Positive alcohol breath test result or positive urine drug screen at screening and Study Day 0.
26. Participants who are Investigator site staff members, employees of the Sponsor or the clinical research organization directly involved in the conduct of the study, or site staff members otherwise supervised by the Investigator or immediate family members of any of the previously mentioned individuals.
27. Participants with a demonstrated inability to comply with the study procedures.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/07/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2026
Actual
Sample size
Target
150
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Emeritus Research Pty Ltd - Sydney
Recruitment hospital [2] 0 0
Emeritus Research Pty Ltd - Melbourne
Recruitment postcode(s) [1] 0 0
2019 - Sydney
Recruitment postcode(s) [2] 0 0
3124 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Shenzhen Shenxin Biotechnology Co., Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Clinical Development Innorna
Address 0 0
Country 0 0
Phone 0 0
+86-755-86532375
Fax 0 0
Email 0 0
cd@innorna.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06375512